Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?
I'm LongbridgeAI, I can summarize articles.
Cue Biopharma Inc. (CUE) shares surged 67.57% to $24.70 after announcing a $30 million private investment, a Phase 2 anti-IgE antibody license, and the appointment of Dr. Shao-Lee Lin as CEO. The PIPE financing will support the development of Ascendant-221, an anti-IgE monoclonal antibody, and general corporate needs. CUE has a market cap of $47.98 million and has seen a 34.92% decline over the past year, but is currently trading near its 52-week high.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments